A new partnership on Earth will help navigate the future of space health. Photo via NASA

Houston's Translational Research Institute for Space Health, or TRISH, has entered into an agreement with the Korea National Institute of Health to collaborate on research and discovery relating to space health.

According to a release, the organizations aim to uncover health findings that can assist in NASA's upcoming Artemis missions, as well as have Earth-bound impacts. The agreement is a Memorandum of Understanding which states that both organizations will "develop fruitful areas of cooperation for space health."

TRISH — which is affiliated with Baylor College of Medicine — and KNIH plan to collaborate on research related to mental health issues due to space travel, the challenges of food supply in deep space, the negative effects of space radiation and en-suite medical care for long-duration space travel.

“As in space, there should be no borders or boundaries to scientific discovery that benefits humankind,” Dorit Donoviel, associate professor in the Center for Space Medicine at Baylor and executive director TRISH said in a statement. “With this agreement, we will work together with the KNIH to collaborate and foster meaningful discussion with the ambition of keeping humans healthy in space and on Earth.”

TRISH announced last month that it will launch six experiments into space aboard Axiom Space's Ax-2 mission in consortium with CalTeach and MIT, which was originally targeted to launch this month.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch in September.

Some of the information found from these missions will become part of TRISH’s Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program, which aims to boost human health on commercial space flights through its database. The program launched in 2021.
Houston-based TRISH's research will be done aboard the Polaris Dawn by its crew, which includes, from left to right, Mission Specialist and Medical Officer Anna Menon, Mission Pilot Scott “Kidd” Poteet, Mission Commander Jared “Rook” Isaacman, Mission Specialist Sarah Gillis. Photo courtesy Polaris Program/John Kraus

Houston space health institute to send experiments on upcoming SpaceX mission

ready for takeoff

The Translational Research Institute for Space Health at Baylor College of Medicine, or TRISH, announced this month that it will perform research experiments aboard SpaceX's upcoming Polaris Dawn mission that will look into everything from human vision to motion sickness to radiation levels while in space.

The research aboard Polaris Dawn will complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit, which was also operated by SpaceX in 2021.

“The Institute’s mission is to help humans thrive in deep space,” Dr. Dorit Donoviel, TRISH executive director and associate professor for the Center for Space Medicine at Baylor, said in a statement. “We are grateful to our commercial space exploration partners, and in particular, the Polaris Program, who recognize how important it is to carry out and support health research in their missions, as a route to improving health for all humans in space and on Earth.”

Polaris Dawn is slated to launch from NASA’s Kennedy Space Center in Florida no earlier than March 2023. It is part of SpaceX's Polaris Program, which proposes three space missions. The first mission aims to reach the highest Earth orbit ever flown.

Four crew members will be onboard SpaceX’s Falcon 9 rocket for the Polaris Dawn mission. TRISH's experiments are part of 38 experiments from institutions that will be conducted on board at high-altitude Earth orbit.

The experiments are supported by federal funding from TRISH's cooperative agreement with NASA, as well as a donation from the Polaris Program.

According to a statement from TRISH, the experiments will include the following:

  • Collecting data related to the vision condition Spaceflight Associated Neuro-Ocular Syndrome (SANS), which is a top risk to human health in long-duration spaceflight
  • Quantifying alterations in body composition and fluid distribution during exposure to weightlessness
  • Directly measuring intracranial pressure changes to quantify the effects of weightlessness on the brain
  • Measuring cognitive performance, which reflects fitness for duty
  • Collecting biometric data to track physiologic changes, which could inform on changes in overall health
  • Using miniaturized, intelligent ultrasound to train the astronauts to scan themselves and deliver medical quality images
  • Testing ways to predict space motion sickness to improve crew safety and in-mission performance
  • Collecting data on the radiation environment to observe how space radiation may affect human systems
  • Providing biological samples for multi-omics analyses and storage in a long-term biobank to be available to researchers in the future

TRISH launched the first-ever commercial spaceflight medical research program in 2021, known as the Expand—Enhancing Exploration Platforms and Analog Definition—Program. Future findings from the Polaris Dawn mission will be added to the database, which compiles in-flight health data from multiple spaceflights.

TRISH was founded in 2016 with the mission of addressing the most pressing health risks and challenges associated with human deep space exploration.

TRISH is seeking space health scientists to support with new initiative. Photo via BCM.edu

Houston organization launches new fellowship to support the future of space health

we have liftoff

A space health-focused organization has announced a new fellowship opportunity for scientists.

The Translational Research Institute for Space Health, or TRISH, housed out of Baylor College of Medicine has announced — along with partners California Institute of Technology and Massachusetts Institute of Technology — a new fellowship opportunity for postdoctoral scientists tackling the health challenges of deep space exploration and innovating solutions.

“TRISH is a launch pad for exceptional postdoctoral fellows investigating new ways to protect human health,” says Rachael Dempsey, education officer for TRISH, in a news release. “Space health science leads to innovations that help humans thrive, wherever they explore. Our institute is committed to building a diverse and engaged workforce prepared for humanity’s future in space.”

TRISH’s postdoctoral fellowship program will select fellows who will then participate in TRISH’s Academy of Bioastronautics — a mentorship community for space health professionals. The professionals will receive a two-year salary stipend as they conduct their work.

“America’s future is in space exploration, and it’s time to invest in the scientists that will bring forward ground-breaking advances to enable that exciting future,” says Dr. Dorit Donoviel, TRISH executive director, in the release.

Those interested can submit their proposals together with an identified mentor and institution online up until January 26, 2023. Independent investigators with existing research grant support may request to be listed as possible mentors for this program by contacting Jean De La Croix Ndong at jndong@nasaprs.com, per the news release.

Supported in part by NASA, Houston-based TRISH is focused on supporting scientists committed to creating space health treatments and solution for the future of space travel.

The human body undergoes specific challenges in space. A new film from TRISH explains the unique phenomenon and how research is helping to improve human life in space. Photo courtesy of NASA

Houston-based organization premieres space health tech documentary

watch now

A Houston space health organization has launched a film that is available to anyone interested in how space affects the human body.

The Translational Research Institute for Space Health, or TRISH, which is housed out of Baylor College of Medicine in consortium with Caltech and the Massachusetts Institute of Technology, announced a new documentary — “Space Health: Surviving in the Final Frontier.” The film, which covers how space affects humans both physically and mentally. It's free to watch online.

“This documentary provides an unprecedented look into the challenges – physical and mental – facing space explorers and the types of innovative research that TRISH supports to address these challenges,” says Dr. Dorit Donoviel, TRISH executive director and associate professor in Baylor’s Center for Space Medicine, in a news release. “We hope the film inspires students and researchers alike to see how their work could one day soon improve the lives of human explorers.”

The documentary interviews a wide range of experts — scientists, flight surgeons, astronauts, etc. — about all topics related to health, like food, medicine, radiation, isolation, and more. Some names you'll see on the screen include:

  • Former NASA astronaut Nicole Stott
  • Active NASA astronaut Victor Glover
  • NASA Associate Administrator Kathy Lueders
  • Inspiration4 Commander Jared Issacman
  • TRISH-funded researchers Level Ex CEO Sam Glassenberg and Holobiome CEO Philip Strandwitz

“Understanding and solving the challenges that face humans in space is critical work,” says Dr. Jennifer Fogarty, TRISH chief scientific officer, in the release. “Not only does space health research aim to unlock new realms of possibility for human space exploration, but it also furthers our ability to innovate on earth, providing insights for healthcare at home.”

TRISH is funded by NASA’s Human Research Program and seeks both early stage and translation-ready research and technology to protect and improve the health and performance of space explorers. This film was enabled by a collaboration with NASA and HRP.

This week's roundup of Houston innovators includes Dorit Donoviel of TRISH, Nuri Firat Ince of UH, and Vanessa Wade of Connect the Dots. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space to engineering — recently making headlines in Houston innovation.


Dorit Donoviel, director of the Translational Research Institute for Space Health

Dorit Donoviel, director of the Translational Research Institute for Space Health

The new program will work with commercial spaceflight crews to bring back crucial research to one database. Photo via Libby Neder Photography

The Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine announced a unique program that will work with commercial spaceflight providers and their passengers. The EXPAND — Enhancing eXploration Platforms and Analog Definition — Program will collect information and data from multiple space flights and organize it in one place. TRISH selected TrialX to build the centralized database.

"The space environment causes rapid body changes. This can help us understand how we humans react to and overcome stress. Ensuring that space explorers remain healthy pushes us to invent new approaches for early detection and prevention of medical conditions," says Dorit Donoviel, executive director at TRISH, in the release.

"Studying a broad range of people in space increases our knowledge of human biology. TRISH's EXPAND program will leverage opportunities with commercial spaceflight providers and their willing crew to open up new research horizons." Click here to read more.

Nuri Firat Ince, associate professor of biomedical engineering at UH

A medical device designed by a UH professor will close the loop with high frequency brain waves to prevent seizures from occurring. Photo via uh.edu

Nuri Firat Ince, an associate professor of biomedical engineering at UH, has received a federal grant aimed at helping stop epileptic seizures before they start. The BRAIN Initiative at the National Institute of Neurological Disorders and Stroke awarded the $3.7 million grant to go toward Ince's work to create a seizure-halting device based on his research.

According to UH, Ince has reduced by weeks the time it takes to locate the seizure onset zone (SOZ), the part of the brain that causes seizures in patients with epilepsy. He's done this by detecting high-frequency oscillations (HFO) forming "repetitive waveform patterns" that identify their location in the SOZ.

"If the outcomes of our research in acute settings become successful, we will execute a clinical trial and run our methods with the implanted … system in a chronic ambulatory setting," Ince says. Click here to read more.

Vanessa Wade, founder and owner of Connect the Dots

It's time for large corporations to step up to support small businesses founded by people of color. Photo courtesy

In her guest column for InnovationMap, Vanessa Wade addressed some of the challenges she faced founding a company as a person of color — specifically the lack of access to funding. In the article, she calls corporations to action to help business leaders like herself.

"The journey ahead can feel discouraging, but the good news is that now I have a much better idea of what it will take to build an equitable road back and get businesses like mine on even footing," she writes. Click here to read more.

The new program will work with commercial spaceflight crews to bring back crucial research to one database. Photo via NASA/Unsplash

Houston organization launches the first commercial spaceflight medical research program

out of this world health care

With commercial space activity reaching cruising altitude, a Houston space health research organization has introduced a new program to create a centralized database.

The Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine announced a unique program that will work with commercial spaceflight providers and their passengers. The EXPAND — Enhancing eXploration Platforms and Analog Definition — Program will collect information and data from multiple space flights and organize it in one place. TRISH selected TrialX to build the centralized database.

As a partner to the NASA Human Research Program, the Houston-based organization's mission is to reduce health risks for astronauts and uncover advances for terrestrial healthcare, according to a news release.

"The space environment causes rapid body changes. This can help us understand how we humans react to and overcome stress. Ensuring that space explorers remain healthy pushes us to invent new approaches for early detection and prevention of medical conditions," says Dorit Donoviel, executive director at TRISH, in the release. "Studying a broad range of people in space increases our knowledge of human biology. TRISH's EXPAND program will leverage opportunities with commercial spaceflight providers and their willing crew to open up new research horizons."

The new collaborative program is meant to address the challenges that humans face on space missions — early detection and treatment of medical conditions, protection from radiation, mental health, team dynamics, and more. TRISH has been working on these challenges since its inception.

"This ground-breaking research model is only possible because everyone — scientists, commercial spaceflight companies, and passengers - recognizes the importance of space health research, and what we can learn by working together," says Dr. Emmanuel Urquieta, TRISH's chief medical officer, in the release.

EXPAND's first collaboration is the Inspiration4 mission, which is launching on September 15. The all-civilian crew will perform a variety of TRISH-supported human health experiments during their time in orbit.

"Shorter commercial space flights like Inspiration4 have similarities to early NASA Artemis missions," says Jimmy Wu, TRISH's senior biomedical engineer. "This allows TRISH an opportunity to test new health and performance technologies for future NASA astronauts."

The potential impact of innovation with this new centralized database and biobank is profound, says James Hury, TRISH's deputy director and chief innovation officer.

"The EXPAND database has the flexibility to seamlessly take in multiple types of data from different flight providers in order to create a repository that can integrate information," says Hury in the release. "A centralized, standardized research database and biobank will increase access to knowledge about human health for the global research community."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.